George Walker Stayer, MD | |
701 Hospital Loop, Fairchild Afb, WA 99011-8704 | |
(092) 475-7555 | |
Not Available |
Full Name | George Walker Stayer |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 701 Hospital Loop, Fairchild Afb, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1518612753 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 35910 (Nebraska) | Primary |
Mailing Address | Practice Location Address |
---|---|
George Walker Stayer, MD 701 Hospital Loop, Fairchild Afb, WA 99011-8704 Ph: (092) 475-7555 | George Walker Stayer, MD 701 Hospital Loop, Fairchild Afb, WA 99011-8704 Ph: (092) 475-7555 |
News Archive
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it has received a Phase 1 Small Business Innovation Research Grant (SBIR) from the National Institute of Allergy and Infectious Disease (NIAID) branch of the National Institutes of Health (NIH) for the further study and characterization of a back-up series of compounds related to its novel antibacterial, ACH-702.
As part of a comprehensive plan to improve student well-being on campus, the University of Michigan has adopted the Okanagan Charter (PDF) and joined the United States Health Promoting Campuses Network, a cohort of seven U.S. universities committed to becoming health-promoting institutions.
Fierce Mobile reports on the recent announcement that PEPFAR is teaming up with the United Nations Foundation, Rockefeller Foundation and Vodafone Foundation to be a founding member of the mHealth Alliance, "a group seeking to bring health services to the most remote corners of the globe using mobile networks and technologies." U.S. Global AIDS Coordinator Eric Goosby announced the partnership during a keynote address last week at the inaugural mHealth Summit in Washington, D.C., according to the news service (Versel, 11/3).
Envoy Therapeutics, Inc., a newly formed drug discovery company, today announced the closing of its first financing, an $8 million private placement of the company's Series A Preferred Stock. Led by 5AM Ventures, other investors participating in the financing included Takeda Research Investment and Roche Venture Fund.
› Verified 5 days ago